Chronic Kidney Disease (CKD)
- Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
- Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
- Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
- Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
- Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis
- Roxadustat for anemia in patients with end-stage renal disease incident to dialysis
- Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study
- Roxadustat for CKD-related Anemia in Non-dialysis Patients
- Anemia in Chronic Kidney Disease
- FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis
Lupus Nephritis
- Obinutuzumab prescribing information
- The Lupus Initiative: Eliminating Health Disparities in Lupus
- KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis
- 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
- Lupus Foundation of America: Lupus Nephritis Information Center
- National Kidney Foundation: Lupus Nephritis
- Lupus Health Disparities in the United States: A Framework of Barriers and Facilitators for Reducing Disease Burden in Racial and Ethnic Minorities
- New Treatment Regimens, New Drugs, and New Treatment Goals for Lupus Nephritis
- Novel Therapeutics for Management of Lupus Nephritis: What Is Next?
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
- Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial
- Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
